Cetera Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cetera Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,956	Closed	-$223K	–	1746
2022 Q4	$223K	Buy	+1,956	New	+$162K	﹤0.01%	1391
2022 Q1	–	Sell	-1,909	Closed	-$206K	–	1558
2021 Q4	$206K	Buy	+1,909	New	+$208K	﹤0.01%	1314
2015 Q4	–	Sell	-14,653	Closed	-$291K	–	774
2015 Q3	$291K	Buy	14,653 +5,662	+63%	+$179K	0.03%	501
2015 Q2	$313K	Buy	8,991 +170	+2%	+$5.19K	0.03%	508
2015 Q1	$229K	Buy	+8,821	New	+$162K	0.02%	592

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cetera Advisors's HZNP Position: Q1 2023 in Review

Cetera Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 1,956 shares — an estimated $223K sold.

Cetera Advisors first reported a position in HZNP in Q1 2015 and held it in 5 quarters. The position peaked at $313K in Q2 2015. 552 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Cetera Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Cetera Advisors sold 1,956 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $223K.
Cetera Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 5 quarters.
Cetera Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $313K in Q2 2015.
552 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Cetera Advisors's 13F filing for Q1 2023, filed 15 May 2023.